Dolan Matthew Vincent's Form 4 filing
Dexcom Inc (DXCM) · filed Mar 14, 2023
- Accession no.
- 0001093557-23-000077
- Filed
- Mar 14, 2023
- Trade date
- Mar 10-13, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions. Open-market sales total $662.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dolan Matthew VincentCIK 0001914994 | Officer (SVP Corporate Strategy-Develop) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 10, 2023 | Common Stock | DReturned to the companyDisposed | −1,370 | $111.40 | −$152,618 | 46,935 | Direct | |
| Mar 10, 2023 | Common Stock | DReturned to the companyDisposed | −1,650 | $111.40 | −$183,810 | 45,285 | Direct | |
| Mar 10, 2023 | Common Stock | DReturned to the companyDisposed | −2,397 | $111.40 | −$267,025.8 | 42,888 | Direct | |
| Mar 10, 2023 | Common Stock | DReturned to the companyDisposed | −787 | $111.40 | −$87,671.8 | 42,101 | Direct | |
| Mar 13, 2023 | Common Stock | SSaleDisposed | −6,229 | $106.27 | −$661,955.83 | 35,872 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.